Table 1. Baseline demographic and... | American Society of Hematology

Table 1.

Baseline demographic and clinical characteristics of treatment-naïve patients

Characteristic	No. (N = 27)	%	Median	Range
Age ≥70 years	3	11	62	48-79
Sex
Male	18	67
Female	9	33
ECOG performance status*
0	1	4
1	26	96
Rai stage†
0, I, or II	18	67
III or IV	9	33
IGHV mutational status
Mutated	3	11
Unmutated	21	78
Data missing	4	11
ZAP-70 (IHC)
Negative	9	33
Positive	17	63
Data missing	1	4
β₂-microglobulin >3.5 mg/L	16	59	4.0	2.0-13.1
White blood cell count × 10⁹/μL			96.6	8.8-321.4
Hemoglobin, g/dL			12.6	8.1-16.3
Platelets × 10⁹/μL			162	77-292

Characteristic	No. (N = 27)	%	Median	Range
Age ≥70 years	3	11	62	48-79
Sex
Male	18	67
Female	9	33
ECOG performance status*
0	1	4
1	26	96
Rai stage†
0, I, or II	18	67
III or IV	9	33
IGHV mutational status
Mutated	3	11
Unmutated	21	78
Data missing	4	11
ZAP-70 (IHC)
Negative	9	33
Positive	17	63
Data missing	1	4
β₂-microglobulin >3.5 mg/L	16	59	4.0	2.0-13.1
White blood cell count × 10⁹/μL			96.6	8.8-321.4
Hemoglobin, g/dL			12.6	8.1-16.3
Platelets × 10⁹/μL			162	77-292

IHC, immunohistochemistry.

Eastern Cooperative Oncology Group (ECOG) performance status ranges from 0 to 5, with 0 indicating no symptoms and higher numbers indicating increasing disability.

†

Rai stage 0 indicates low-risk, stage I or II intermediate-risk, and stage III or IV high-risk disease.

View Large

This Feature Is Available To Subscribers Only